
    
      Participants 18 to < 65 years of age on enrollment will be randomized to receive either
      Fluzone Quadrivalent or Fluzone Intradermal vaccine. Participants â‰¥ 65 years of age at
      enrollment will be randomized to receive either Fluzone Quadrivalent or Fluzone High-Dose
      vaccine.

      Solicited adverse event (AE) information will be collected for 7 days after each vaccination,
      unsolicited AE and Serious adverse event information will be collected from Visit 1 to Visit
      2. Total duration of participation in the study is approximately 21 days.
    
  